Overview

Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the microbiological and clinical outcome of treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator. Finafloxacin shows increased activity in an acidic environment which is associated with indications such as uUTI and cUTI. Given the acidic pH of urine and concentration of finafloxacin excreted via the urinary tract in humans it should be proven if the finafloxacin treatments offer significant advantages over the currently available treatments for UTI.
Phase:
Phase 2
Details
Lead Sponsor:
MerLion Pharmaceuticals GmbH
Treatments:
Ciprofloxacin
Finafloxacin
Fluoroquinolones